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for identifying T cells. The vast majority of
chronic lymphocytic leukaemias (CLL) was
shown to be a monoclonal B cell proliferation
with a maturation block. However biclonal
proliferations were encountered and a T cell
origin was proven in 3 out of 150 CLL. The
abnormal cells in 14 patients with the Sezary
syndrome were identified as T cells. In most
patients with common acute lymphoblastic
leukaemia, no B or T markers were detected
at the surface of the abnormal cells. These
cells possessed neo antigens reactive with non
anti-B antibodies present in antisera to CLL
cells. In 30% ofthe cases the T nature ofthe
blast cells appeared likely. In 11 other ALL
patients a monoclonal B cell proliferation was
found. These patients were usually not
affected with common ALL and belonged
mostly to two specific entities; in 3 cases the
blastic proliferation supervented in patients
previously affected with common CLL and in
6 cases the blast cells possessed all the
cytological features ofBurkitt's tumour cells.
B and T cell markers were also assessed in
more than 30 cases ofnon-Hodgkin malignant
lymphomata. Well-differentiated lympho-
cytic lymphomata and nodular lymphomata
were found to be ofB cell origin. Most ofour
cases of diffuse poorly differentiated lympho-
cytic lymphoma behaved as B cell monoclonal
malignancies. The so-called reticulum cell
sarcomata probably represent a hetero-
geneous group. In most cases the large
malignant cells appeared to be devoid of B or
T cellmarkers. However in one case a strong
affinity receptor for IgG was found and was
suggestive of a true histiocytic origin. In 3
patients in whom reticulum cell sarcoma
supervened on a previous lymphoid malig-
nancy (chronic lymphocytic leukaemia or
Waldenstrom macroglobulinaemia) the large
sarcoma cells belonged to the B cell series and
presumably originated from the same clone as
the previous lymphoid proliferation sincethey
bore the same immunoglobulin chains.
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SURFACE ANTIGENS OF
LEUKAEMIC CELLS
M. F. GREAVES, University College London.
Over the past few years the development
ofthe technology for identifying the selective
expression of cell surface markers on various
populations oflymphoid cellshas been a major
contribution towards our current under-
standing of the organization and function of
the immune system (Greaves, Owen and Raff,
1973). Inprinciplethisapproachshouldalsobe
applicable to the analysis of leukaemias,
lymphomata and in fact malignant cells in
general. Thus ifa panel ofcell surface markers
is available which in combination provide a
cell surface phenotype characteristic of a par-
ticular lymphocyte cell type, say a T cell, then
the presence of a similar cell surface profile on
a leukaemic cell might be taken to indicate
that the latter may have arisen from T cells.
This type of investigation might provide a
cell refinement to the diagnosis of lympho-
reticular malignancies and also insight into
the origin and aetiology of the disease
(Brown et al., 1974; Harris, 1973).
Another approach to the identification of
leukaemic cells which may hold out even
more promise involves the use of antisera
which may define cell surface antigens of
leukaemic cells which are either entirely
restricted to those cells or are at least absent
from normal lymphoreticular cells. There is
a long history of attempts to produce such
discriminating antisera (reviewed in Harris,REPORT OF THE LEUKAEMIA RESEARCH FUND 281
1973 and Seligmann et al., 1973), generally
however one must conclude that until very
recently there was no convincing evidence for
success. Recently, however, several en-
couraging results have been reported. For
example, Metzgar and colleagues (Monhana-
kumar, Metzgar and Miller, 1974) have
raised antisera in monkeys which appear to
distinguish different leukaemic cells from
each other and from normal cells. Baker and
Taub (Baker, Ramachander and Taub, 1975)
have raised antisera in mice rendered tolerant
to normal lymphocyte antigens, which appear
to have similar properties.
We have raised antisera in rabbits to
acute lymphoblastic leukaemic (ALL) cells by
injecting these cells coated with antibodies to
normal lymphocytes. The binding of the
antisera to various cell types has been studied
using immunofluorescent reagents and the
analytical capacity of the Fluorescence
Activated Cell Sorter-I (FACS-1) and their
full characteristics are described fully else-
where (Greaves et al., 1975; Brown, Capellaro
and Greaves, 1975). In summary, after
absorption with red cells, liver and tonsil
lymphocytes, the anti-ALL sera do not react
with normal resting or dividing foetal or
adult lymphocytes and appear on the basis of
absorption studies to define three leukaemia
associated antigens.
1. A " weak " antigen shared with my-
elocytes, myeloblastic leukaemia cells
and foetal liver (haemopoietic) cells,
2. A strong antigen shared with a subset of
intermediate normoblasts found in
normal bone marrow and early foetal
liver, and
3. An antigen found so far only on non-T
cell ALLs, which we regard as a strong
candidate for a leukaemia specific
antigen.
We have used antisera to ALL to distin-
guish between non-T ALL, T cell type ALL
and other acute leukaemias in untreated
patients and more recently have begun to
screen patients considered to be in remission
for rare leukaemic cells which migbt indicate
residual disease and/or early signs of relapse.
The results indicate that leukaemic cells are
demonstrable in remission patients. Analy-
sis of cell populations with antileukaemic sera
may therefore have important diagnostic and
prognostic potential.
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NEOPLASMS OF THE IMMUNE
SYSTEM: CLASSIFICATION BY
PRESUMED CELL OF ORIGIN
R. D. COLLINS, Vanderbilt University School
of Medicine, Nashville, Tennessee.
Current classifications of malignant
lymphomata were developed before the
complexities of the immunological system
were recognized, and are defective by not
providing a conceptual approach to the
relationship between lymphoid neoplasms
and normal lymphocyte populations. Lukes
and Collins (1974a, b) have recently outlined a
classification oflymphoid neoplasms based on
modern concepts of the immune system, as
well as histological features (Table I). The
basic tenet of this proposal is that malignant
lymphomata, as neoplasms of the immune
system, should be classified according to the
kind of lymphocyte from which they arise.
Although the clinical usefulness of this
proposed classification has not been tested,
preliminary studies indicate that most
lymphoid neoplasms may be satisfactorily
categorizedbyacombinationoffunctionaland
structural investigations.
For example, in a recent study at Vander-
bilt (Leech et al., 1974; Glick et al., 1974), cells